je.st
news
Tag: extendedrelease
Pfizer Announces FDA Approval Of XELJANZ XR (tofacitinib citrate) Extended-Release Tablets, The First And Only Once-Daily Oral JAK Inhibitor Treatment For Rheumatoid Arthritis
2016-03-02 04:30:55| drugdiscoveryonline Home Page
Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved XELJANZ XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX)
Tags: treatment
approval
oral
announces
Do Extended-Release Dewormers Have Resistance Concerns?
2014-10-09 21:01:46| Beef
Over the past several years, veterinarians and parasitologists have raised concerns about the potential for internal cattle parasites to develop resistance to deworming products. At the same time, it’s long been known that cattle deworming is a management practice that can pay a producer back in terms of cattle performance. That produces a conundrum; to deworm or not to deworm. Fortunately, it’s not an either-or proposition. read more
Tags: concerns
resistance
extendedrelease
Results from HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
2013-03-09 18:50:00| Merck.com - Research & Development News
Dateline City: SAN FRANCISCO SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) during a late-breaking clinical trials session at the American College of Cardiology 62nd Annual Scientific Sessions (abstract 300-14). Language: English Contact HTML: MerckMedia:Pamela Eisele, 908-423-5042Skip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
american
study
college
Merck Provides Update on Next Steps for TREDAPTIVE (extended-release niacin/laropiprant)
2013-01-11 13:39:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE (extended-release niacin/laropiprant) tablets worldwide. TREDAPTIVE is not approved for use in the United States. Language: English Contact HTML: MerckMedia:Pamela Eisele, 908-423-5042orSkip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
steps
merck
extendedrelease
Sites : [1]